Immunologic and Transcriptomic Comparison of Patients with COVID19 and other Infection at Point of Admission  

In contrast to intensive care research, there is a paucity of research in the field of acute infection, as patients do not present at predictable times and either rapidly get better or, rarely, die from infection; the BioAID bioresource was set up to address this gap. BioAID continued to recruit samples throughout the first wave of COVID19 admissions (current total ~900 since March 2020) providing a valuable resource of  'time zero' RNA and serum samples and negative control/non COVID19 samples. The aim of this project is to compare the cytokine and transcriptomic profiles of patients admitted with COVID19, with those admitted with bacterial sepsis and other viral infections, in order to provide context and better understanding of COVID19 pathogenesis. We hope that the transcriptomic data may also serve to enhance any new diagnostic signatures for COVID-19 infection. The samples and data will also  support the validation of prognostic biomarkers for the national ISARIC-4C cohort of COVID-19 patients